Name | neriifolin |
---|---|
Synonyms |
NERIIFOLIN
17Beta-Neriifolin xy)-14-hydroxy digitoxigenin+thevetose |
Description | Neriifolin, a CNS-penetrating cardiac glycoside, is an inhibitor of the Na+, K+-ATPase. Neriifolin can target beclin 1, inhibits the formation of LC3-associated phagosomes and ameliorates experimental autoimmune encephalomyelitis (EAE) development. Neriifolin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells[1][2. |
---|---|
Related Catalog | |
In Vitro | Neriifolin (0.1μg/mL; 48 hours) induces apoptosis in HepG2 cells. Neriifolin (0-8 μg/mL; 72 hours) reduces viability of HepG2 cells. Neriifolin also induces S and G2/M phase arrests of the cell cycle and stimulates apoptosis of HepG2 cells. Stimulation of HepG2 cells with Neriifolin induced activation of caspase-3, -8, and -9, and up-regulated expression of Fas and FasL proteins[1]. |
References |
Density | 1.274g/cm3 |
---|---|
Boiling Point | 700.079ºC at 760 mmHg |
Melting Point | 218-225ºC |
Molecular Formula | C30H46O8 |
Molecular Weight | 534.68100 |
Flash Point | 224.862ºC |
Exact Mass | 534.31900 |
PSA | 114.68000 |
LogP | 3.11020 |
Vapour Pressure | 0mmHg at 25°C |
Index of Refraction | 1.581 |
Hazard Codes | T+ |
---|---|
Risk Phrases | 26/27/28 |
Safety Phrases | 22-36/37/39-45 |
RIDADR | UN 2811 6.1/PG 1 |
WGK Germany | 3 |
RTECS | FH4906100 |